July 28, 2014
Biologic treatments for RA carry similar infection risk
effrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating rituximab, abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.
- Alternate Title Link: http://medicalxpress.com/news/2014-07-biologic-treatments-ra-similar-infection.html